INTERIM REPORT

Q3 2022

THE POWER OF PRECISION. FOR EVERY ONCOLOGIST. TODAY.

2curex

HIGHLIGHTS AND KEY FIGURES

OVERWHELMING FEEDBACK FROM ONCOLOGISTS
During the term of the third quarter of 2022 we obtained overwhelming confirmation, through the externally conducted study "Oncologists' attitude towards Functional DrugSensitivity Testing", which documents a high degree of support and reaffirmation for the need of new tools that support therapy decision-making in colorectal cancer.

As we exit the third quarter of 2022, we are now present in a total of 17 countries, which since last quarter includes our new distributor in Romania as well as strengthened position in Portugal. Our updated goal and expectation are to reach a total of 20 countries as 2022 comes to an end.

Our early access program, IGNITE, continues to be very well received by the oncologists. The progress and enrollment did not develop quite as planned, which is the result of a low summer activity as well as a longer than expected processes to formalizing agreements. In Q3 2022 we have a total of 15 hospitals and expectations are to reach a total of 20 IGNITE agreements by the end 2022.

FINANCIAL HIGHLIGHTS
The financial development is in line with our plans and expectations, and with a cash position of SEK 47,8 million at the end of Q3 2022, our capital resources can support the current activities and growth plans.

(KSEK)	**Q3 2022** *1/7-30/9*	**Q3 2021** *1/7-30/9*	**Q1-Q3 2022** *1/1-30/9*	**Q1-Q3 2021** *1/1-30/9*	**2021** *1/1-31/12*
Net sales	0	0	8	0	0
Other operating income	395	530	1 295	4 850	7 391
Profit before tax	-8 353	-6 393	-22 653	-15 202	-21 679
Earnings per share (SEK)*	-0,47	-0,31	-1,29	-0,79	-1,10
Equity ratio**	93%	96%	93%	96%	94%
Cash and bank	47 820	72 498	47 820	72 498	72 942
Average number of shares	17 602 916	17 463 442	17 573 562	16 054 288	16 418 767
No. of shares by the end of the period	17 602 916	17 475 716	17 602 916	17 475 716	17 475 716

**Earnings per share: Profit for the period divided by the average number of shares.*

***Equity ratio: Shareholder's equity divided by total capital.*

HIGHLIGHTS IN 2022

2022

APR
- Chairman of the 2cureX Board exercises all warrants within the framework of the 2018 incentive program
- Manuel Fernández joins 2cureX as Director of Quality Assurance and Regulatory Affairs.
- Notice of annual general meeting of 2cureX AB

MAY
- 2cureX publishes the annual report for the fiscal year 2021
- Redeye research interview with 2cureX CEO, Fernando Andreu
- 2cureX appoints Sedermera Corporate Finance AB to act as a liquidity provider for the Company's share
- 2cureX presents IndiTreat® clinical results at the Society for Functional Precision Medicine

JUNE
- 2cureX AB announces share purchase by the company's Chairman of the Board of Directors and Executive Management
- 2cureX expands distribution of IndiTreat® to Israel

JULY
- Dr. Raphael Gruber joins 2cureX as new Medical Director
- Notice of extra general meeting in 2cureX AB

AUG
- Announcement from 2cureX extra general meeting approving warrant package for board member Dr. Michael Schaefer
- 2cureX publishes interim report for the second quarter and first half of 2022

SEP
- 2cureX expands distribution of IndiTreat® to Romania
- 2cureX announces the strengthening the relationship with Werfen to include Portugal
- 2cureX terminates liquidity provision service

OCT
- 2cureX celebrates co-inventor of patents awarded Nobel Prize in Chemistry
- Independent market survey shows great demand for 2cureX product portfolio

NOV
- 2cureX hosted a deep dive session of its operational and commercial strategy

MAY
- IGNITE update: Eight hospitals have been enrolled in the program
- Presenting Dr. Michael Schaefer in regards to the nomination to the Board of Directors
- Three IndiTreat® posters have been accepted at ESMO-GI 2022
- 2cureX publishes interim report for the first quarter 2022 and presents in live webcast
- 2cureX announces new distributer in Finland

FOR MORE INFORMATION PLEASE CONTACT:

Fernando Andreu, CEO
Mail: fa@2curex.com
Mobile: +45 2279 5399

Ole Thastrup, CSO
Mail: ot@2curex.com
Mobile: +45 2211 5399

www.2curex.com

INDEPENDENT CONFIRMATION OF THE INTEREST IN INDITREAT®

In the third quarter of 2022 we received very important, independent confirmation about the need for new tools to support therapy decision-making in colorectal cancer. The unequivocal response of the oncologists to our survey shows that we are addressing a real clinical need, and the survey clearly strengthens a general belief that Functional Drug Sensitivity Testing will over time become the standard to select the best therapy for each individual patient.

OVERWHELMING CONFIRMATION OF THE CLINICAL NEED AND INTENTION TO USE

In Q3 2022, the results of the study "Oncologists' attitudes towards Functional Drug Sensitivity Testing", commissioned by 2cureX to the German company 2HMForum, were published. 140 gastrointestinal oncologists from Scandinavia, Spain and Poland answered questions about their current treatment practices, and their knowledge and attitudes towards Functional Drug Sensitivity Testing (f-DST).

The survey confirmed that oncologists do not currently have any tools for personalization based on expected response of a patient to a treatment. Participants massively supported the idea that "New tools to support therapy decision-making in colorectal cancer are urgently needed" (91% of participants), confirming this is a real and present unmet clinical need.

Oncologists strongly believe that f-DST can be a useful tool to help select the right treatment for an individual patient. 67% responded positively to that statement and only 11% disagreed. Among those who agreed to the statement, 83% said that f-DST "provides a guidance for drugs that do not have an associated biomarker", and 55% said that "Genomics-only cannot predict the response profile of a patient".

An overwhelming 76% indicated they "would like to try a Drug Sensitivity Test with my patients". Only 7% responded negatively. This extremely positive response confirms previous findings, and the oncologists' feedback received directly by 2cureX when introducing IndiTreat®.

Finally, 53% of oncologists responded positively to "I would use IndiTreat® Start with my patients to select 1st Line treatment, and 61% did the same for IndiTreat® Extend and Explore for 3rd Line treatment. These percentages can be considered high, given that f-DST tests are in early stages and not yet included in guidelines.

INDITREAT® PRESENT IN 17 COUNTRIES

In Q3 2022 we signed a distribution agreement with the company Onco Systems to bring IndiTreat® to Romania. Romania is one of Europe's largest countries, with a population of 19.4 M people, and has 13,000 new colorectal cancer (CRC) cases every year. With this agreement, IndiTreat® is represented in 17 countries, and the goal of 20 countries by the end of 2022 is at reach.

We have also extended the existing contract with Werfen to cover Portugal in addition to Spain and Andorra. As a global leader in IVD, Werfen is in an excellent position to leverage the synergies between two very close countries like Spain and Portugal, and the expansion of the agreement is a sign of their positive perspectives about the development of the f-DST market.

15 HOSPITALS HAVE BEEN ENROLLED IN THE IGNITE PROGRAM

IGNITE is our early access program, where qualified hospitals can receive – for a limited period – IndiTreat® tests for

free, in exchange for sharing their experience with other potential users. This program has been very well received by oncologists, and by the end of Q2 2022 we had 12 hospitals enrolled. In Q3 2022 we saw a slower enrollment than planned, mainly due to the low activity in the summer period and very long processes to formalize the agreements (requiring reviews by the legal departments of the hospitals that can take several months. We have finished Q3 2022 with 15 hospitals and expect to reach 20 hospitals at year end. Some hospitals have suggested it's easier for them to use the format of a classic clinical study, as they already have a streamlined legal and administrative process for such studies. We will therefore offer both options going forward to fulfill the interest of oncologists in trying IndiTreat in their hospitals.

We see increased clinical and commercial activities in the area of f-DST. In a very complex socioeconomic environment, we keep our commitment to make IndiTreat® a success and bring the benefits of personalized medicine to all colorectal cancer patients throughout the different stages of their disease. Functional Drug Sensitivity Testing will become the standard way of choosing the right therapy for an individual patient, creating a multi-billion-dollar opportunity. With the continued support of our shareholders and the commitment of our employees, 2cureX is and will continue to be the leader in this new space.

Fernando Andreu, *CEO*
November 24, 2022

2CUREX IN BRIEF

The key product of 2cureX is the IndiTreat® test portfolio, which allows the physician to identify the most efficient medical treatment for a particular cancer patient.

For more details see 2cureX's website at
www.2curex.com

BREAKING THROUGH THE BARRIERS OF A COMPLEX PROCESS

THE PATH TO SALES

For a new medical technology to be used in clinical routine once it receives regulatory clearance (CE marking in Europe) three steps need to be covered.

The first one relates to awareness. The relevant stakeholders, in our case oncologists and pathologists, need to be aware of the existence of f-DST and its benefits. This is achieved through being present in conferences, presentations at hospitals – thus the importance of an extensive sales network in each country –, publications, webinars, social media.

The second step is the willingness to use it. The stakeholders need to be willing to use the products based on the new technology, and here we see different profiles of customers based on how they relate to innovation. "Innovators" and "Early Adopters" are the first to come on board, but they need to have tested the products themselves and confirmed they work according to the expectations. These groups are our immediate focus and for them we are offering clinical studies or alternatively the IGNITE program. The "Early Majority" is a customer profile that will use the test only if other oncologists are using it, and there is a critical mass of evidence (publications, studies, etc.). So, this segment is not open for f-DST short term, as is not the third wave of customers – the "Late Majority" – who will only use the test when it is recommended in guidelines (see the Technology Adoption Curve in the Strategy Deep-dive section).

Once a new product has the endorsement of the clinical stakeholders, the purchasing decision-making is mainly in the hands of "economic decision-makers", and that's the third step. These are different in a public or a private environment and based on country specific differences. There is not a Europe-wide solution to this, and that's why having local distributors in each country is so important. The stakeholders in these negotiations are hospital managers, economic directors, insurance companies, reimbursement bodies. Marginal pathways where patients pay out of pocket are possible in some countries – not all – but they still require the recommendation from the oncologist.

PROGRESS OF THE IGNITE PROGRAM

IGNITE is our early access program, where qualified hospitals can receive – for a limited period – IndiTreat® tests for free, in exchange for sharing their experience with other potential users. This program was conceived to attract the Innovators and Early Adopters in the different countries and has been very well received by oncologists. By the end of Q2 2022 we had 12 hospitals enrolled and were aiming at 20 hospitals at the end of Q3 2022. Despite having ongoing conversations with more than 40 hospitals as of now, only 15 are enrolled by the end of Q3 2022. The main reason for the delay is the longer than anticipated decision-making times due to the summer holiday season and the very long processes to formalize the agreements – requiring reviews by the legal departments of the hospitals that can take several months. We have consequently revised our end of year goal from 30 to 20 hospitals.

The program is a good way to expose potential customers to the benefits of IndiTreat®, and we will continue to offer it. It is notable that we are not receiving rejections of the technology or of IndiTreat® but delays due to internal legal and administrative processes that are much longer than expected. This has led some hospitals to suggest a classic clinical study could be a faster way, since the approval

process for these studies is sometimes more streamlined. We will be offering both options to hospitals, so they can choose the one that fits best their situation. What is important is the extremely positive feedback that we keep receiving from oncologists, and their willingness to try IndiTreat in their hospitals. This makes us confident we are in the right path forward to capture a considerable share of the addressable f-DST market.

EXPANDING TO THE ROMANIAN MARKET AND STRENGTHENING OUR POSITION IN PORTUGAL

In Q3 2022 we signed an additional distribution agreement, this time with the company Onco Systems who became the distributor of IndiTreat® products in Romania. With a population of 19.4 M people, Romania is one of Europe's largest countries, and this agreement makes IndiTreat® available to the 13,000 patients that are diagnosed with colorectal cancer (CRC) in the country each year. With this agreement, IndiTreat® is represented in 17 countries, and the goal of 20 countries by year end is at reach.

We also announced in Q3 2022 the change in distributor in Portugal, where Lab52 was replaced by Werfen through an extension of the current agreement in Spain and Andorra. As a global leader in IVD, Werfen is an excellent position to leverage the synergies between two very close countries like Spain and Portugal, and the expansion of the agreement must be seen as a sign of their positive perspectives about the development of the f-DST market.

ENCOURAGED BY THE RESPONSE OF THE MARKET

Despite the IGNITE delay, we feel very encouraged by the response of the oncologists, reflected in our daily interactions and in their responses to our survey (see the specific section in this report for details). We see strong signals that the market is developing, as indicated by the growing number of companies, the interest from customers and distributors and the increasing accumulated investment in this segment, and we remain optimistic about capturing a significant share of the market as it further develops in the coming years.



ASSESSING ONCOLOGISTS' ATTITUDES TOWARDS f-DST

In Q3 2022, the results of a study commissioned by 2cureX to the German company 2HM forum were published. Through the study "Oncologist's attitudes towards Functional Drug Sensitivity Testing" 2HM surveyed 140 experienced oncologists, specialized in gastrointestinal (GI) cancers from Scandinavia – home market for 2cureX –, Spain – largest country with IndiTreat® distribution – and Poland – second largest country with IndiTreat® distribution. The survey was conducted between June and August 2022 and participants were asked to respond to 36 questions about their current treatment practices, and their knowledge and attitudes towards Functional Drug Sensitivity Testing (f-DST).



A CONFIRMATION OF THE CLINICAL NEED INDITREAT® IS ADDRESSING

The survey confirmed that the chemotherapy backbones used in metastatic colorectal cancer (mCRC) treatment are the same across countries, and the selection of which drug to use is made based on toxicity profile of the drug, patient preference or hospital protocol. There is, therefore, no personalization based on expected response of the patient to the treatment. Participants massively supported that "New tools to support therapy decision-making in colorectal cancer are urgently needed" (91% of participants), summarizing the strong evidence that this is a real and present unmet clinical need.

HIGH EXPECTATION FOR f-DST

Oncologists strongly believe that Drug Sensitivity Testing can be a useful tool to help select the right treatment for an individual patient. 67% responded positively to that statement and only 11% disagreed. Among those who agreed to the statement, 83% said that f-DST "provides a guidance for drugs that do not have an associated biomarker", and 55% said that "Genomics-only cannot predict the response profile of a patient"

An overwhelming 76% clearly indicated they "would like to try a Drug Sensitivity Test with my patients". Only 7% responded negatively. This extremely positive response confirms previous findings and the oncologists' feedback received directly by 2cureX when introducing IndiTreat®.

HIGH "INTENTION TO USE" FOR THE CURRENT INDITREAT® PORTFOLIO

53% of oncologists responded positively to "I would use IndiTreat® Start with my patients to select 1st Line treatment, and 61% did the same for IndiTreat® Extend and Explore for 3rd Line treatment. Typically, Innovators and Early Adopters represent less than 20% of the market, so these percentages can be considered high, given that f-DST tests are in early stages and not yet included in guidelines. It is to be expected that these percentages of "intention to use" will grow dramatically when there's a critical mass of customers using the test and when the test is included in guidelines.

DEVELOPMENT DURING Q3 AND YTD 2022, IN FIGURES

Numbers within parentheses refer to the corresponding period in the preceding year. For additional information about 2cureX's financial position and development, please refer to the Company's website *(www.2cureX.com)*.

NET SALES AND OPERATING INCOME
Net sales for the first nine months of 2022 amounted to 8 KSEK (0 KSEK). Other operating income for the first nine months of 2022 amounted to 1 295 KSEK (4 850 KSEK), and during the third quarter of 2022 to 395 KSEK (530 KSEK).

FINANCIAL DEVELOPMENT
The result during the first nine months of 2022 amounted to -22 653 KSEK (-12 727 KSEK) and for the third quarter of 2022 the result amounted to -8 353 KSEK (-5 427 KSEK). The result for the period has been impacted by the increasing efforts to build the market awareness of our IndiTreat® technology, and commercial efforts to market IndiTreat®.

LIQUIDITY
The Group's cash and cash equivalents amounted to 47 820 KSEK (72 498 KSEK) as of September 30, 2022. Cash flow during the first nine months of 2022 amounted to -25 382 KSEK (13 650 KSEK) and for the third quarter of 2022 cash flow amounted to -7 780 KSEK (-6 561 KSEK). Cash flow from operating activities in the first nine months of 2022 amounted to -25 076 KSEK (-17 794 KSEK) and in the third quarter of 2022 cash flow from operating activities amounted to -7 740 KSEK (-8 131 KSEK). The monthly average burn rate is approximately 3.3 MSEK, which is in line with the expectations.

SOLIDITY
The Group's equity ratio as of September 30, 2022 amounted to 93 percent (96).

THE SHARE
There is one class of shares in 2cureX AB (publ). The Company's share is listed on Nasdaq First North Growth Market under the ticker "2CUREX". As of September 30, 2022, the number of shares amounted to 17 602 916 (17 475 716).

The average number of shares during the first nine months of 2022 amounted to 17 602 916 (17 475 716).

WARRANT PROGRAM FOR EMPLOYEES AND BOARD MEMBERS
The extra general meeting on November 5, 2020 resolved to establish a warrant program for three new board members. The warrant program totalling 120,000 warrants carry the right to subscribe for newly issued shares in 2cureX AB in the period from October 1, 2023 up to an including December, 31, 2023. Each subscription warrant entitles the holder to subscribe for 1 share, at a subscription price equal to 110 percent of the volume weighted average price at Nasdaq First North Growth Market during a period of ten trading days following the extra general meeting on November 5, 2020. Upon full exercise of the issued warrants, the share capital would increase by 12,000 SEK. The warrants will be subject to the usual conversion terms in connection with new share issues etc.

The Annual General Meeting on May 27, 2021 resolved to establish a Series 2021/24 warrant program for the Group's CEO. The warrants, totalling 700 000 warrants, carry the right to subscribe for newly issued shares in 2cureX AB in the period April 1, 2022 to 30 June 2022 (233 333 warrants), in the period that lasted April 1, 2023 to June 30, 2023 233 333 warrants) and in the period April 1, 2024 to June 30, 2024 (233 334 warrants), respectively

The Group's result for the first nine months of 2022 has been impacted by costs in the amount of 943 KSEK (863 KSEK) in the form of personnel costs.

POLICIES FOR THE PREPARATION OF THE INTERIM FINANCIAL REPORT
2cureX AB applies the Swedish Annual Accounts Act as well as the Swedish Accounting Standards Board BFNAR 2012:1 annual report and consolidated (K3) in the preparation of its financial reports.

AUDITORS' REVIEW
This interim report has not been reviewed by the Company's auditors.

CORPORATE GOVERNANCE

The 2cureX group consists of a holding company, 2cureX AB (publ) (Sweden) that is listed at Nasdaq First North Growth Market, and two operational companies 2cureX A/S (Denmark) and 2cureX GmbH (Germany). 2cureX AB and 2cureX A/S have the same Board of Directors who has the overall responsibility of the governance structure for the 2cureX group.

Corporate governance is linked to compliance with Nasdaq First North Growth Market Rulebook and laws and regulations relevant for 2cureX.

Key aspects of the governance structure relate to shareholder's meetings, Article of Association, the composition of the Board of Director's and Board's annual wheel. The board of Directors has implemented relevant policies and procedures for 2cureX.



BOARD OF DIRECTORS

POVL-ANDRÉ BENDZ
Chairman of 2cureX AB and 2cureX A/S



MICHAEL SCHAEFER
Board member of 2cureX AB and 2cureX A/S

OLE THASTRUP
Board member and CSO of 2cureX AB and 2cureX A/S

CAMILLA HUSE BONDESSON
Board Member of 2cureX AB and 2cureX A/S

NILS BRÜNNER
Board member of 2cureXAB and 2cureX A/S

MICHAEL LUTZ
Board member of 2cureX AB and 2cureX A/S

CLINICAL ADVISORY BOARD

DR. JOHN L. MARSHALL
MD is Chief, Hematology and Oncology at Georgetown University Hospital, and Professor of Medicine and Oncology at Georgetown University in Washington D.C.

DR. JESUS GARCIA-FONCILLAS
MD PhD is currently the Director of the University Cancer Institute and the Department of Oncology at the University Hospital "Fundacion Jimenez Diaz" in Spain.

DR. ANDREW BEGGS
is currently Professor of Cancer Genetics & Surgery at the Institute of Cancer and Genomic Sciences and Co-Lead of Molecular Oncology, Pathology and Genetics, University of Birmingham, UK.

MANAGEMENT

FERNANDO ANDREU
CEO

KENNETH G. JOHANSEN
CFO

OLE THASTRUP
CSO and Deputy CEO

RAPHAEL GRUBER
Medical Director

GRITH HAGEL
VP Innovation and Technology Development

JÜRGEN KUPPER
Managing Director (2cureX GmbH)

JESPER FLOYD KRISTIANSEN
VP Business Development Europe

MARK GRAY
Director of Communications

MANUEL FERNANDEZ
Director Quality & Regulatory

TABEA STURMHEIT
Director of Research

JACOB THASTRUP
Director of Product Development

FINANCIAL CALENDAR

The Company prepares and publishes a financial report at the end of each quarter. Upcoming reports are planned to be released as follows:

- **Year-End Report 2022 .....23/02 2023**
- **Interim Report Q1 2023 ..... 25/05 2023**
- **Annual General Meeting 25/05 2023**
- **Interim Report Q2 2023 ..... 24/08 2023**
- **Interim Report Q3 2023 .....23/11 2023**

DELIVERY OF INTERIM REPORT

Landskrona, November 24, 2022 2cureX AB

BOARD OF DIRECTORS

Povl-André Bendz
Chairman of the Board

Michael Schaefer
Member of the Board

Camilla Huse Bondesson
Member of the Board

Michael Lutz
Member of the Board

Ole Thastrup
Member of the Board and CSO

Nils Brünner
Member of the Board

Fernando Andreu
CEO

CERTIFIED ADVISER
Redeye AB

FINANCIAL STATEMENTS

FINANCIAL OVERVIEW THE GROUP

SUMMARY OF INCOME STATEMENT –THE GROUP (KSEK)	**Q3 2022** *1/7-30/9*	**Q3 2021** *1/7-30/9*	**Q1-Q3 2022** *1/1-30/9*	**Q1-Q3 2021** *1/1-30/9*	**2021** *1/1-31/12*
Operating income					
Net sales	0	0	8	0	0
Other operating income	395	530	1 295	4 850	7 391
Total operating income	**395**	**530**	**1 303**	**4 850**	**7 391**
Operating expenses					
Other external expenses	-3 404	-2 262	-9 721	-7 447	-11 863
Personnel costs	-6 319	-4 733	-16 395	-12 611	-17 976
Depreciation of tangible fixed assets	-78	-90	-226	-275	-353
Total operating expenses	**-9 801**	**-7 085**	**-26 342**	**-20 333**	**-30 192**
Operating profit	**-9 406**	**-6 555**	**-25 039**	**-15 483**	**-22 801**
Financial posts	1 053	162	2 386	281	322
Profit before tax	**-8 353**	**-6 393**	**-22 653**	**-15 202**	**-22 479**
Tax [1]	0	966	0	2 475	3 542
The result of the period	**-8 353**	**-5 427**	**-22 653**	**-12 727**	**-18 937**
Earnings per share (SEK)	-0,47	-0,31	-1,29	-0,79	-1,15
Average number of shares	17 602 916	17 463 442	17 573 562	16 054 288	16 418 767
No. of shares at the end of the period	17 602 916	17 475 716	17 602 916	17 475 716	17 475 716

[1] *This post refers to tax relief in subsidiaries regarding R&D work.*

SUMMARY OF BALANCE SHEET – THE GROUP (KSEK)	**Q1-Q3 2022** *1/1-30/6*	**Q1-Q3 2021** *1/1-30/9*	**2021** *1/1-31/12*
Assets			
Fixed assets			
Tangible fixed assets	822	768	691
Total fixed assets	**822**	**768**	**691**
Current assets			
Receivables	5 631	8 558	5 527
Cash and bank balances	47 820	72 498	72 942
Total current assets	**53 451**	**81 056**	**78 469**
Total assets	**54 273**	**81 824**	**79 160**
Equity and liabilities			
Equity			
Share capital	1 760	1 748	1 748
Ongoing share issue	0	0	1 068
Other contributed capital	107 664	106 608	106 608
Other equity	-36 101	-17 232	-16 143
The result of the period	-22 653	-12 727	-18 937
Total equity	**50 670**	**78 397**	**74 344**
Current liabilities			
Short-term liabilities [2)]	3 603	3 427	4 816
Total short-term liabilities	**3 603**	**3 427**	**4 816**
Total equity and liabilities	**54 273**	**81 824**	**79 160**

SUMMARY OF CASH FLOW – THE GROUP (KSEK)	**Q3 2022** *1/7-30/9*	**Q3 2021** *1/7-30/9*	**Q1-Q3 2022** *1/1-30/9*	**Q1-Q3 2021** *1/1-30/9*	**2021** *1/1-31/12*
Cash flow from operating activities	-7 740	-8 131	-25 076	-17 794	-18 426
Cash flow from investment activities	-40	-11	-306	-38	-32
Cash flow from financing activities	0	1 581	0	31 482	32 550
Cash flow for the period	**-7 780**	**-6 561**	**-25 382**	**13 650**	**14 092**
Cash and cash equivalents at the beginning of the period	55 583	30 018	72 942	58 577	58 577
Exchange rate difference in cash and cash equivalents	17	131	260	271	273
Cash and cash equivalents at the end of the period	**47 820**	**63 977**	**47 820**	**72 498**	**72 942**

CHANGE OF EQUITY – THE GROUP

1/1-2021 – 30/9-2021

(KSEK)	Share capital	Other contributed capital	Other equity	Result of the period	Total
At the beginning of the period (1/1-2021)	**1 486**	**75 388**	**-10 690**	**-7 320**	**58 864**
Outline of previous year's results			-7 320	7 320	0
Issue of shares	262	33 188			33 450
Issue cost		-1 968			-1 968
Allocation of staff warrants			863		863
Translation difference			-85		-85
The result of the period				-12 727	-12 727
At the end of the period (30/9-2021)	**1 748**	**106 608**	**-17 232**	**-12 727**	**78 397**

1/1-2022 – 30/9-2022

(KSEK)	Share capital	Ongoing share issue	Other contributed capital	Other equity	Result of the period	Total
At the beginning of the period (1/1-2022)	**1 748**	**1 068**	**106 608**	**-16 143**	**-18 937**	**74 344**
Outline of previous year's results				-18 937	18 937	0
Registration of share issue	12	-1 068	1 056			0
Translation difference				-1 964		1 964
Allocation of staff warrants				943		943
The result of the period					-22 653	-22 653
At the end of the period (30/9-2022)	**1 760**	**0**	**107 664**	**-36 101**	**-22 653**	**50 670**

FINANCIAL OVERVIEW PARENT COMPANY

SUMMARY OF INCOME STATEMENT – PARENT COMPANY (KSEK)	**Q3 2022** *1/7-30/9*	**Q3 2021** *1/7-30/9*	**Q1-Q3 2022** *1/1-30/9*	**Q1-Q3 2021** *1/1-30/9*	**2021** *1/1-31/12*
Operating income					
Net sales	0	0	0	0	0
Total operating income	**0**	**0**	**0**	**0**	**0**
Operating expenses					
Other external expenses	-410	-303	-1 186	-1 303	-1 898
Staff costs	-424	-316	-982	-572	-839
Total operating expenses	**-834**	**-619**	**-2 168**	**-1 875**	**-2 737**
Operating profit	**-834**	**-619**	**-2 168**	**-1 875**	**-2 737**
Financial posts	177	-321	66	-153	-1 072
Profit before tax	**-657**	**-940**	**-2 102**	**-2 028**	**-3 809**
Tax	0	0	0	0	0
The result of the period	**-657**	**-940**	**-2 102**	**-2 028**	**-3 809**

SUMMARY OF BALANCE SHEET – PARENT COMPANY (KSEK)	**Q1-Q3 2022** *1/1-30/9*	**Q1-Q3 2021** *1/1-30/9*	**2021** *1/1-31/12*
Assets			
Fixed assets			
Financial assets	50 284	5 000	29 275
Total fixed assets	**50 284**	**5 000**	**29 275**
Current assets			
Receivables	792	24 765	552
Cash and bank balances	45 240	66 518	67 176
Total current assets	**46 032**	**91 283**	**67 728**
Total assets	**96 316**	**96 283**	**97 003**
Equity and liabilities			
Equity			
Share capital	1 760	1 748	1 748
Premium fund	111 864	110 808	110 808
Ongoing share issue	0	0	1 068
Balanced result	-16 031	-14 329	-13 165
The result of the period	-2 102	-2 028	-3 809
Total equity	**95 491**	**96 199**	**96 650**
Current liabilities			
Current liabilities	825	84	353
Total short-term liabilities	**825**	**84**	**353**
Total equity and liabilities	**96 316**	**96 283**	**97 003**

SUMMARY OF CASH FLOW – PARENT COMPANY (KSEK)	**Q3 2022** *1/7-30/9*	**Q3 2021** *1/7-30/9*	**Q1-Q3 2022** *1/1-30/9*	**Q1-Q3 2021** *1/1-30/9*	**2021** *1/1-31/12*
Cash flow from operating activities	-885	-2 944	-1 936	-2 925	-3 335
Cash flow from investment activities	-5 000	0	-20 000	0	0
Cash flow from financing activities	0	1 581	0	31 482	32 550
Cash flow for the period	**-5 885**	**-1 363**	**-21 936**	**28 557**	**29 215**
Cash and cash equivalents at the beginning of the period	51 125	67 881	67 176	37 961	37 961
Cash and cash equivalents at the end of the period	**45 240**	**66 518**	**45 240**	**66 518**	**67 176**

CHANGE OF EQUITY – PARENT COMPANY

1/1-2021 – 30/9-2021

(KSEK)	Share capital	Other contributed capital	Other equity	Result of the period	Total
At the beginning of the period (1/1-2021)	**1 486**	**79 588**	**-13 164**	**-2 028**	**65 882**
Outline of previous year's results			-2 028	2 028	0
Issue of shares	262	33 188			33 450
Issue costs		-1 968			-1 968
Allocation of staff warrants			863		863
The result of the period				-2 028	-2 028
At the end of the period (30/9-2021)	**1 748**	**110 808**	**-14 329**	**-2 028**	**96 199**

1/1-2022 – 30/9-2022

(KSEK)	Share capital	Ongoing share issue	Other contributed capital	Other equity	Result of the period	Total
At the beginning of the period (1/1-2022)	**1 748**	**1 068**	**110 808**	**-13 165**	**-3 809**	**96 650**
Outline of previous year's results				-3 809	3 809	0
Allocation of staff warrants				943		943
Registration of share issue	12	-1 068	1 056			0
The result of the period					-2 102	-2 102
At the end of the period (30/9-2022)	**1 760**	**0**	**111 864**	**-16 031**	**-2 102**	**95 491**

THE POWER OF PRECISION. FOR EVERY ONCOLOGIST. TODAY.

2CUREX AB (publ)

Corporate registration number: **559128-0077**

2CUREX A/S

Fruebjergvej 3 / DK-2100 Copenhagen / Denmark

Phone: +45 2211 5399 / E-mail: info@2curex.com